Department of Pulmonology, Division of Heart & Lungs, University Medical Centre Utrecht, PO Box 85500, Utrecht 3508 GA, The Netherlands.
Faculty of Health, Medicine and Life Science, Maastricht University, Maastricht, The Netherlands; Department of Respiratory Medicine, ILD Center of Excellence, St. Antonius Hospital, Nieuwegein, The Netherlands; ILD Care Foundation Research Team, Heideoordlaan 8, Ede 6711NR, The Netherlands.
Clin Chest Med. 2024 Mar;45(1):91-103. doi: 10.1016/j.ccm.2023.08.005. Epub 2023 Sep 4.
Sarcoidosis is an immune-mediated multisystem granulomatous disorder. Neurosarcoidosis (NS) accounts for 5% to 35% of cases. The diagnostic evaluation of NS can be a clinical challenge. Gadolinium-enhanced magnetic resonance imaging (MRI) is the gold standard to evaluate central nervous system NS. In almost all cases treatment is warranted. Although glucocorticoids remain the first-line therapy in patients with sarcoidosis, in NS timely initiation of second- or third-line treatment is strongly recommended. Of these, tumor necrosis factor-alpha inhibitors are the most promising. However, the treatment itself may be responsible for/associated with developing neurologic symptoms mimicking NS. Thus, it is important to consider the possibility of drug-induced neurologic symptoms in sarcoidosis.
结节病是一种免疫介导的多系统肉芽肿性疾病。神经结节病(NS)占病例的 5%至 35%。NS 的诊断评估可能具有临床挑战性。钆增强磁共振成像(MRI)是评估中枢神经系统 NS 的金标准。几乎所有病例都需要治疗。尽管糖皮质激素仍然是结节病患者的一线治疗药物,但强烈建议及时启动二线或三线治疗。其中,肿瘤坏死因子-α抑制剂最有前途。然而,治疗本身可能会导致/与模仿 NS 的神经症状相关。因此,重要的是要考虑结节病中药物引起的神经症状的可能性。